Loading...

LKSH

LAKESHORE BIOPHARMA CO LTD

()

2024 6-K

Acquisition Proposal

25 Mar '26

EGM Postponement

6 Feb '26

Legal Dispute Update

29 Jan '26

Shareholder Meeting

20 Jan '26

Going Private Agreement

4 Nov '25

Market Transition

22 Sep '25

Delisting Notice

12 Sep '25

New Advisor Announcement

10 Sep '25

Acquisition Proposal

28 Aug '25

Acquisition Proposal

18 Aug '25

Financial Results Report

31 Jul '25

Control Change

15 Jul '25

Financing Announcement

8 Jul '25

Chairman Change

12 May '25

Financing Lease Agreement

6 May '25

Court Ruling Announcement

25 Mar '25

Incentive Plan Update

12 Mar '25

Financial Report

19 Dec '24

Criminal Investigation Update

12 Dec '24

Auditor Change

12 Nov '24

Vaccine Application Initiated

7 Nov '24

Management Change

1 Nov '24

Regains Compliance

29 Oct '24

Clinical Trial Approval

25 Oct '24

Financial Guidance Update

8 Oct '24

Share Consolidation

27 Sep '24

Filing Amendment

10 Sep '24

Shareholder Meeting Notice

10 Sep '24

Leadership Transition

4 Sep '24

Financial Results Announced

15 Aug '24

Extraordinary Meeting

5 Jul '24

Management Changes

18 Jun '24

Board Restructuring

10 Jun '24

Name Change Notice

24 May '24

Extraordinary Meeting Results

21 May '24

Company Updates

7 May '24

Compliance Extension Granted

29 Apr '24

Financial Results Update

19 Apr '24

Vaccine Trial Approval

18 Apr '24

Positive Vaccine Results

9 Apr '24

Loan Repayment

3 Apr '24

Leadership Changes

5 Mar '24

Ownership Update

23 Feb '24

General Meeting Results

22 Feb '24

Change in Control

20 Feb '24

General Meeting Update

16 Feb '24

Extraordinary Meeting Notice

14 Feb '24

Board Changes

14 Feb '24

Director Removal

14 Feb '24

Private Placement Announcement

9 Feb '24

Financial Default Notice

26 Jan '24

YS Biopharma Filing

22 Jan '24

6-K Filing Summary

8 Jan '24

External Links:

SEC

YS Biopharma Co., Ltd. will hold an extraordinary general meeting on May 21, 2024, to approve a name change to LakeShore Biopharma, appoint new directors, and adopt a 2024 Share Incentive Plan involving 5,713,064 shares. Additionally, Mr. Dave Chenn has been appointed as Interim CEO effective May 2, 2024.

AI Assistant

LAKESHORE BIOPHARMA CO LTD

2024

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.